Varian Medical Systems Selected for New Proton Therapy Center in Sweden | Varian

{ "pageType": "news-article", "title": "Varian Medical Systems Selected for New Proton Therapy Center in Sweden", "articleDate": "20 de August de 2009", "introText": "", "category": "Oncology" }

Varian Medical Systems Selected for New Proton Therapy Center in Sweden

STOCKHOLM, Aug. 20 /PRNewswire-FirstCall/ -- Varian Medical Systems (NYSE: VAR) today announced it has been selected to equip a new proton therapy center in Sweden. In a ceremony conducted by Swedish authorities yesterday following a public tender, Varian was named to supply an estimated $60 million in products for Skandionkliniken, a new national proton therapy center owned by a consortium of seven of Sweden's counties. The center is scheduled to open in 2013. Varian hopes to book the order for the project before the end of the fiscal year upon review and approval of the tender process.

Public officials representing Skandionkliniken publicly announced the award here on Aug. 19 when they met with Varian Medical Systems management to sign the contract. Skandionkliniken is the first clinical center for proton therapy in Scandinavia.

"We are honored to be selected for this important project following a competitive bidding process and a thorough review of our proton therapy technology by numerous experts from across Sweden's radiation oncology community," said Varian President and CEO Tim Guertin. "This will be our first full installation for managing, planning, and delivering proton therapy, which we believe will be a powerful weapon in the battle to cure cancer. This award is a major milestone for the Varian Particle Therapy business."

Skandionkliniken, which will have two full treatment rooms as well as a fixed beam room for quality assurance and research activities, is expected to treat 1,000 patients per year in phase 1, and gradually expand to the full capacity of 2,500 patients per year. Varian will equip the center with a fully integrated system including its superconducting cyclotron, a beam line, and treatment room gantries as well as its ARIA® software for information management and its Eclipse™ software for treatment planning. Varian will also have a five year service agreement valued at approximately $25 million.

"Varian's advanced technology for spot scanning was of decisive importance in our choice of supplier," said Leif Lyttkens, Managing Director of Skandionkliniken. "We are pleased to be working with Varian, which has proven to be a reliable partner with leading edge solutions for cancer treatment." Spot scanning makes it possible to deliver intensity-modulated proton therapy to concentrate the dose on the targeted tumor while sparing normal healthy tissues.

Proton therapy makes it possible to treat cancer more effectively and with fewer side effects than with conventional radiation therapy. With proton therapy, the risk of damage to healthy tissues is minimized. The method can be applied for the most common types of cancer and offers advantages when treating tumors close to radiosensitive tissues. In pediatric patients the risk of developing a new, radiation-induced cancer later in life is reduced. Skandionkliniken expects that most of the children in need of radiotherapy will be offered proton treatments.

The project marks the first time that the seven Swedish counties, representing eight university hospitals, have made a joint investment in a national center for cancer treatment. Under this collaborative model, university hospitals in each county will manage and plan proton treatments locally, and treat their patients at the new center.

The proton therapy consortium, called "The Joint Authority of County Councils for Advanced Radiation Therapy," was formed by the seven counties in 2006. The seven counties are: Uppsala, Ostergotland, Skane, Stockholm, Vasterbotten, Vastra Gotaland and Orebro. All eight University Hospitals in Sweden (Uppsala, Linkoping, Lund, Malmo, Stockholm, Umea, Goteborg and Orebro) will treat patients at Skandionkliniken. The public tender for the proton therapy system was issued in 2008.

Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies X-ray imaging products for cargo screening and industrial inspection. Varian Medical Systems employs approximately 5,100 people who are located at manufacturing sites in North America, Europe, and China and approximately 79 sales and support offices around the world. For more information, visit

Forward-Looking Statements

Except for historical information, this news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements concerning industry outlook, including growth drivers; the company's future orders, revenues, backlog, or earnings growth; future financial results; market acceptance of or transition to new products or technology for proton therapy;, and any statements using the terms "expect," "hope," or similar statements are forward-looking statements that involve risks and uncertainties that could cause the company's actual results to differ materially from those anticipated. Such risks and uncertainties include the effect of economic conditions, currency exchange rates and tax rates; demand for the company's products; the company's ability to develop and commercialize new proton therapy products; the company's reliance on sole or limited-source suppliers; the company's ability to maintain or increase operating margins; the completion of the public tender process; the company's ability to meet regulatory regulations or procedures; the company's ability to protect the company's intellectual property; the potential loss of key personnel; and the other risks listed from time to time in the company's filings with the Securities and Exchange Commission, which by this reference are incorporated herein. The company assumes no obligation to update or revise the forward-looking statements in this release because of new information, future events, or otherwise.

    Spencer Sias (650) 424-5782

    Meryl Ginsberg (650) 424-6444

SOURCE Varian Medical Systems, Inc.

SOURCE: Varian Medical Systems, Inc.

Web site: